Loading clinical trials...
Loading clinical trials...
90-day Postoperative Morbidity and Mortality After Elective Surgery for Gastric Cancer
Gastric cancer is still one of the main health care issue and gastrectomy with lymph node dissection is the only chance to be cure. Trials show that the postoperative course differs significantly between eastern and western centers, as well as between clinics within Russian Federation. Postoperative 30-day postoperative mortality after gastric cancer surgery ranges from 1% to 5%, and postoperative complication rates range from 10% to 40%. To improve the quality of further studies and recommendations for standardization of surgical treatment of gastric cancer and its complications, there is a need to study the differences in 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation.
According to 2018 World Health Organization (WHO) data, gastric cancer is the fourth most common malignant disease and the third leading cause of cancer-related deaths worldwide. Surgery with lymphadenectomy remains the standard of care. Despite significant changes in gastric cancer treatment protocols, surgery is still associated with high risks of complications, with rates varying from clinic to clinic. And currently, the use of multimodal treatments and standardization of surgical procedures are proposed as strategies to improve outcomes. In addition, the use of laparoscopic and robotic techniques have been proposed to provide better short-term results compared to open surgery and comparable long-term oncological outcomes. Randomized trials show that the postoperative course differs significantly between eastern and western centers, as well as between clinics within Russian Federation. Postoperative 30-day postoperative mortality after gastric cancer surgery ranges from 1% to 5%, and postoperative complication rates range from 10% to 40%. While mortality is easier to quantify, there are no standardized criteria for calculating postoperative complication rates. To improve the quality of further studies and recommendations for standardization of surgical treatment of gastric cancer and its complications, there is a need to study the differences in 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
A.S. Loginov Moscow Clinical Scientific Center
Moscow, Russia
A.Tsyb Medical Radiological Research Centre
Moscow, Russia
I.M. Sechenov First Moscow State Medical University
Moscow, Russia
P.Herzen Moscow Oncological Research Institute
Moscow, Russia
Petrovsky National Research Centre of Surgery
Moscow, Russia
Vishnevsky National Medical Research Center of Surgery
Moscow, Russia
Nizhny Novgorod Regional Clinical Oncological Dispensary
Nizhny Novgorod, Russia
National Medical Research Centre for Oncology
Rostov-on-Don, Russia
Petrov National Medical Research Center of Oncology
Saint Petersburg, Russia
Start Date
March 18, 2024
Primary Completion Date
September 18, 2024
Completion Date
December 31, 2024
Last Updated
February 26, 2024
700
ESTIMATED participants
Elective Surgery for gastric cancer
PROCEDURE
Lead Sponsor
P. Herzen Moscow Oncology Research Institute
Collaborators
NCT04550494
NCT04704661
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions